Automate Your Wheel Strategy on ARDX
With Tiblio's Option Bot, you can configure your own wheel strategy including ARDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARDX
- Rev/Share 1.6462
- Book/Share 0.6378
- PB 12.1675
- Debt/Equity 1.3457
- CurrentRatio 4.4129
- ROIC -0.0939
- MktCap 1885478240.0
- FreeCF/Share -0.2288
- PFCF -34.0659
- PE -33.1973
- Debt/Assets 0.427
- DivYield 0
- ROE -0.3691
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ARDX | Piper Sandler | Neutral | Overweight | -- | -- | Jan. 9, 2026 |
| Resumed | ARDX | Raymond James | -- | Strong Buy | -- | $14 | Sept. 3, 2025 |
| Resumed | ARDX | H.C. Wainwright | -- | Buy | -- | $10 | June 18, 2025 |
| Downgrade | ARDX | Raymond James | Strong Buy | Outperform | -- | $11 | May 2, 2025 |
| Resumed | ARDX | Ladenburg Thalmann | -- | Buy | -- | -- | March 7, 2025 |
| Initiation | ARDX | BTIG Research | -- | Buy | -- | $14 | March 4, 2025 |
News
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Read More
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Call End: Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2024 Earnings Conference Call February 20, 2025 8:00 A.M. ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & CEO Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz – Citigroup Dennis Ding – Jefferies Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Julian Harrison – BTIG Ryan Deschner - Raymond James Thomas Yip - H.C.
Read More
Ardelyx (ARDX) Meets Q4 Earnings Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Ardelyx (ARDX) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Read More
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales
Read More
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
Read More
About Ardelyx, Inc. (ARDX)
- IPO Date 2014-06-19
- Website https://www.ardelyx.com
- Industry Biotechnology
- CEO Michael G. Raab
- Employees 395